ESR1 and breast cancer: Here using integrated genomic and functional studies, we report that amplification and/or overexpression of the COP9 complex-associated isopeptidase COPS5 is presented in about 9% of the ERα+ primary breast cancer and more frequently (86.7%, 26/30) in tamoxifen-resistant tumours.